Antengene receives Thailand FDA approval to commercialize Xpovio in Thailand: Shanghai Tuesday, September 24, 2024, 13:00 Hrs [IST] Antengene Corporation Limited, a leading innova ...
US FDA approves anti-CD38 therapy, Sarclisa in combo with standard-of-care treatment for adult patients with NDMM who are not eligible for transplant: Paris Tuesday, September 24, ...
Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...
The 21st annual meeting of the International Myeloma Society takes place September 25-28, 2024, in Rio de Janiero, Brazil.
This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...
two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. The ASEAN region, with its steady economic growth and a population ...
The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...
The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients ...
In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & Johnson), also carries a first-line indication for transplant-ineligible MM ...
Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...
The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback